Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

Bin Qiu; Kaican Cai; Chun Chen; Jun Chen; Ke Neng Chen; Qi Xun Chen; Chao Cheng; Tian Yang Dai; Junqiang Fan; Zhaohui Fan; Jian Hu; Wei Dong Hu; Yun Chao Huang; Ge Ning Jiang; Jie Jiang; Tao Jiang; Wen Jie Jiao; He Cheng Li; Qiang Li; Yong De Liao; Hong Xu Liu; Jun Feng Liu; Lunxu Liu; Yang Liu; Hao Long; Qing Quan Luo; Hai Tao Ma; Nai Quan Mao; Xiao Jie Pan; Fengwei Tan; Li Jie Tan; Hui Tian; Dong Wang; Wen Xiang Wang; Li Wei; Nan Wu; Qing Chen Wu; Jiaqing Xiang; Shi Dong Xu; Lin Yang; Hao Zhang; Lanjun Zhang; Peng Zhang; Yi Zhang; Zhenfa Zhang; Kunshou Zhu; Yuming Zhu; Sang Won Um; In Jae Oh; Yusuke Tomita; Satoshi Watanabe; Takeo Nakada; Nobuhiko Seki; Toyoaki Hida; Shinji Sasada; Junji Uchino; Haruhiko Sugimura; Said Dermime; Federico Cappuzzo; Stefania Rizzo; William Chi Shing Cho; Pierfilippo Crucitti; Filippo Longo; Kye Young Lee; Dirk De Ruysscher; Ben G.L. Vanneste; Muhammad Furqan; Jessica C. Sieren; Sai Yendamuri; Kenneth W. Merrell; Julian R. Molina; Giulio Metro; Raffaele Califano; Stefano Bongiolatti; Mariano Provencio; Paul Hofman; Shugeng Gao; Jie He

doi:10.21037/tlcr-21-634

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

Bin Qiu, Kaican Cai, Chun Chen, Jun Chen, Ke Neng Chen, Qi Xun Chen, Chao Cheng, Tian Yang Dai, Junqiang Fan, Zhaohui Fan, Jian Hu, Wei Dong Hu, Yun Chao Huang, Ge Ning Jiang, Jie Jiang, Tao Jiang, Wen Jie Jiao, He Cheng Li, Qiang Li, Yong De LiaoHong Xu Liu, Jun Feng Liu, Lunxu Liu, Yang Liu, Hao Long, Qing Quan Luo, Hai Tao Ma, Nai Quan Mao, Xiao Jie Pan, Fengwei Tan, Li Jie Tan, Hui Tian, Dong Wang, Wen Xiang Wang, Li Wei, Nan Wu, Qing Chen Wu, Jiaqing Xiang, Shi Dong Xu, Lin Yang, Hao Zhang, Lanjun Zhang, Peng Zhang, Yi Zhang, Zhenfa Zhang, Kunshou Zhu, Yuming Zhu, Sang Won Um, In Jae Oh, Yusuke Tomita, Satoshi Watanabe, Takeo Nakada, Nobuhiko Seki, Toyoaki Hida, Shinji Sasada, Junji Uchino, Haruhiko Sugimura, Said Dermime, Federico Cappuzzo, Stefania Rizzo, William Chi Shing Cho, Pierfilippo Crucitti, Filippo Longo, Kye Young Lee, Dirk De Ruysscher, Ben G.L. Vanneste, Muhammad Furqan, Jessica C. Sieren, Sai Yendamuri, Kenneth W. Merrell, Julian R. Molina, Giulio Metro, Raffaele Califano, Stefano Bongiolatti, Mariano Provencio, Paul Hofman, Shugeng Gao, Jie He

Medical Oncology

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Pages (from-to)	3713-3736
Number of pages	24
Journal	Translational Lung Cancer Research
Volume	10
Issue number	9
DOIs	https://doi.org/10.21037/tlcr-21-634
State	Published - Sep 2021

ASJC Scopus subject areas

Oncology

Access to Document

10.21037/tlcr-21-634

Cite this

Qiu, B., Cai, K., Chen, C., Chen, J., Chen, K. N., Chen, Q. X., Cheng, C., Dai, T. Y., Fan, J., Fan, Z., Hu, J., Hu, W. D., Huang, Y. C., Jiang, G. N., Jiang, J., Jiang, T., Jiao, W. J., Li, H. C., Li, Q., ... He, J. (2021). Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. Translational Lung Cancer Research, 10(9), 3713-3736. https://doi.org/10.21037/tlcr-21-634

Qiu, B, Cai, K, Chen, C, Chen, J, Chen, KN, Chen, QX, Cheng, C, Dai, TY, Fan, J, Fan, Z, Hu, J, Hu, WD, Huang, YC, Jiang, GN, Jiang, J, Jiang, T, Jiao, WJ, Li, HC, Li, Q, Liao, YD, Liu, HX, Liu, JF, Liu, L, Liu, Y, Long, H, Luo, QQ, Ma, HT, Mao, NQ, Pan, XJ, Tan, F, Tan, LJ, Tian, H, Wang, D, Wang, WX, Wei, L, Wu, N, Wu, QC, Xiang, J, Xu, SD, Yang, L, Zhang, H, Zhang, L, Zhang, P, Zhang, Y, Zhang, Z, Zhu, K, Zhu, Y, Um, SW, Oh, IJ, Tomita, Y, Watanabe, S, Nakada, T, Seki, N, Hida, T, Sasada, S, Uchino, J, Sugimura, H, Dermime, S, Cappuzzo, F, Rizzo, S, Cho, WCS, Crucitti, P, Longo, F, Lee, KY, De Ruysscher, D, Vanneste, BGL, Furqan, M, Sieren, JC, Yendamuri, S, Merrell, KW, Molina, JR, Metro, G, Califano, R, Bongiolatti, S, Provencio, M, Hofman, P, Gao, S & He, J 2021, 'Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer', Translational Lung Cancer Research, vol. 10, no. 9, pp. 3713-3736. https://doi.org/10.21037/tlcr-21-634

@article{797b85de1eb340738a3c8d93b2e4ebec,

title = "Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer",

author = "Bin Qiu and Kaican Cai and Chun Chen and Jun Chen and Chen, {Ke Neng} and Chen, {Qi Xun} and Chao Cheng and Dai, {Tian Yang} and Junqiang Fan and Zhaohui Fan and Jian Hu and Hu, {Wei Dong} and Huang, {Yun Chao} and Jiang, {Ge Ning} and Jie Jiang and Tao Jiang and Jiao, {Wen Jie} and Li, {He Cheng} and Qiang Li and Liao, {Yong De} and Liu, {Hong Xu} and Liu, {Jun Feng} and Lunxu Liu and Yang Liu and Hao Long and Luo, {Qing Quan} and Ma, {Hai Tao} and Mao, {Nai Quan} and Pan, {Xiao Jie} and Fengwei Tan and Tan, {Li Jie} and Hui Tian and Dong Wang and Wang, {Wen Xiang} and Li Wei and Nan Wu and Wu, {Qing Chen} and Jiaqing Xiang and Xu, {Shi Dong} and Lin Yang and Hao Zhang and Lanjun Zhang and Peng Zhang and Yi Zhang and Zhenfa Zhang and Kunshou Zhu and Yuming Zhu and Um, {Sang Won} and Oh, {In Jae} and Yusuke Tomita and Satoshi Watanabe and Takeo Nakada and Nobuhiko Seki and Toyoaki Hida and Shinji Sasada and Junji Uchino and Haruhiko Sugimura and Said Dermime and Federico Cappuzzo and Stefania Rizzo and Cho, {William Chi Shing} and Pierfilippo Crucitti and Filippo Longo and Lee, {Kye Young} and {De Ruysscher}, Dirk and Vanneste, {Ben G.L.} and Muhammad Furqan and Sieren, {Jessica C.} and Sai Yendamuri and Merrell, {Kenneth W.} and Molina, {Julian R.} and Giulio Metro and Raffaele Califano and Stefano Bongiolatti and Mariano Provencio and Paul Hofman and Shugeng Gao and Jie He",

note = "Funding Information: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi. org/10.21037/tlcr-21-634). Dr. IJO has grant from Roche; he also has received consulting fee from Roche, Ono, MSD, Pfizer, Boehringer-Ingelheim, AstraZeneca and Takeda. Dr. YT reports grants from JSPS KAKENHI grant number JP18K15928 and grants from Takeda Science Foundation outside the submitted work. Dr. SW reports grant and personal fee from AstraZeneca and Boehringer Ingelheim, personal fee from Chugai Pharma, Ono Pharmaceutical, Bristol-Myers, Eli Lilly, MSD, Taiho Pharmaceutical, Pfizer, Novartis, Daiichi Sankyo. Dr. RC has received consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AZ, MSD, BMS, Roche, TAKEDA, Pfizer, janssen, Bayer, Novartis; Dr. RC has Participation on a Data Safety Monitoring Board or Advisory Board with AZ, MSD, BMS, Roche, TAKEDA, Pfizer, janssen, Bayer, Novartis; Dr. RC has received Support for attending meetings and/ or travel from Roche, MSD, Takeda; Dr. RC declares stock ownership with The christie private care. Dr. KM reports medical education grant, Africa from Varian and Pfizer, Clinical trial grant from AstraZeneca and Novartis; travel and accommodations to a clinical trial meeting, 2019 from AstraZeneca; Dr. KM is an unpaid Board of Directors of Global Access to Cancer Care Foundation. Dr. JCS has grant support from National Institute of Health and the Noah{\textquoteright}s Hope Foundation; she also has a family member that owns stock options and receives financial compensation from Vida Diagnostics. Dr. MF participated in advisory board for Astrazeneca, AbbVie and Beigene LLC. Dr. DDR reports grants from Bristol-Myers Squibb, grants from AstraZeneca, grants from Boehringer Ingelheim, from Philips, from Olink, from Celgene, from Seattle Genetics, from Roche/Genentech, from Merck/Pfizer, outside the submitted work. Dr. FC reports fees for membership of an advisory board from Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, Pharmamar, Novocure and MSD. Dr NS obtained commercial research grants from Eli Lilly, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, and Nippon Boehringer Ingelheim, and has received speaking honoraria from Eli Lilly, AstraZeneca, MSD Oncology, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, Nippon Boehringer Ingelheim, and Bristol-Myers Squibb Japan. TH serves as an unpaid editorial board member of Translational Lung Cancer Research from Jan 2020 to Dec 2021. FC serves as an unpaid editorial board member of Translational Lung Cancer Research from Aug 2021 to Jul 2023. MF serves as an unpaid editorial board member of Translational Lung Cancer Research from",

year = "2021",

month = sep,

doi = "10.21037/tlcr-21-634",

language = "English (US)",

volume = "10",

pages = "3713--3736",

journal = "Translational Lung Cancer Research",

issn = "2218-6751",

publisher = "Society for Translational Medicine (STM)",

number = "9",

}

TY - JOUR

T1 - Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

AU - Qiu, Bin

AU - Cai, Kaican

AU - Chen, Chun

AU - Chen, Jun

AU - Chen, Ke Neng

AU - Chen, Qi Xun

AU - Cheng, Chao

AU - Dai, Tian Yang

AU - Fan, Junqiang

AU - Fan, Zhaohui

AU - Hu, Jian

AU - Hu, Wei Dong

AU - Huang, Yun Chao

AU - Jiang, Ge Ning

AU - Jiang, Jie

AU - Jiang, Tao

AU - Jiao, Wen Jie

AU - Li, He Cheng

AU - Li, Qiang

AU - Liao, Yong De

AU - Liu, Hong Xu

AU - Liu, Jun Feng

AU - Liu, Lunxu

AU - Liu, Yang

AU - Long, Hao

AU - Luo, Qing Quan

AU - Ma, Hai Tao

AU - Mao, Nai Quan

AU - Pan, Xiao Jie

AU - Tan, Fengwei

AU - Tan, Li Jie

AU - Tian, Hui

AU - Wang, Dong

AU - Wang, Wen Xiang

AU - Wei, Li

AU - Wu, Nan

AU - Wu, Qing Chen

AU - Xiang, Jiaqing

AU - Xu, Shi Dong

AU - Yang, Lin

AU - Zhang, Hao

AU - Zhang, Lanjun

AU - Zhang, Peng

AU - Zhang, Yi

AU - Zhang, Zhenfa

AU - Zhu, Kunshou

AU - Zhu, Yuming

AU - Um, Sang Won

AU - Oh, In Jae

AU - Tomita, Yusuke

AU - Watanabe, Satoshi

AU - Nakada, Takeo

AU - Seki, Nobuhiko

AU - Hida, Toyoaki

AU - Sasada, Shinji

AU - Uchino, Junji

AU - Sugimura, Haruhiko

AU - Dermime, Said

AU - Cappuzzo, Federico

AU - Rizzo, Stefania

AU - Cho, William Chi Shing

AU - Crucitti, Pierfilippo

AU - Longo, Filippo

AU - Lee, Kye Young

AU - De Ruysscher, Dirk

AU - Vanneste, Ben G.L.

AU - Furqan, Muhammad

AU - Sieren, Jessica C.

AU - Yendamuri, Sai

AU - Merrell, Kenneth W.

AU - Molina, Julian R.

AU - Metro, Giulio

AU - Califano, Raffaele

AU - Bongiolatti, Stefano

AU - Provencio, Mariano

AU - Hofman, Paul

AU - Gao, Shugeng

AU - He, Jie

N1 - Funding Information: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi. org/10.21037/tlcr-21-634). Dr. IJO has grant from Roche; he also has received consulting fee from Roche, Ono, MSD, Pfizer, Boehringer-Ingelheim, AstraZeneca and Takeda. Dr. YT reports grants from JSPS KAKENHI grant number JP18K15928 and grants from Takeda Science Foundation outside the submitted work. Dr. SW reports grant and personal fee from AstraZeneca and Boehringer Ingelheim, personal fee from Chugai Pharma, Ono Pharmaceutical, Bristol-Myers, Eli Lilly, MSD, Taiho Pharmaceutical, Pfizer, Novartis, Daiichi Sankyo. Dr. RC has received consulting fees, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AZ, MSD, BMS, Roche, TAKEDA, Pfizer, janssen, Bayer, Novartis; Dr. RC has Participation on a Data Safety Monitoring Board or Advisory Board with AZ, MSD, BMS, Roche, TAKEDA, Pfizer, janssen, Bayer, Novartis; Dr. RC has received Support for attending meetings and/ or travel from Roche, MSD, Takeda; Dr. RC declares stock ownership with The christie private care. Dr. KM reports medical education grant, Africa from Varian and Pfizer, Clinical trial grant from AstraZeneca and Novartis; travel and accommodations to a clinical trial meeting, 2019 from AstraZeneca; Dr. KM is an unpaid Board of Directors of Global Access to Cancer Care Foundation. Dr. JCS has grant support from National Institute of Health and the Noah’s Hope Foundation; she also has a family member that owns stock options and receives financial compensation from Vida Diagnostics. Dr. MF participated in advisory board for Astrazeneca, AbbVie and Beigene LLC. Dr. DDR reports grants from Bristol-Myers Squibb, grants from AstraZeneca, grants from Boehringer Ingelheim, from Philips, from Olink, from Celgene, from Seattle Genetics, from Roche/Genentech, from Merck/Pfizer, outside the submitted work. Dr. FC reports fees for membership of an advisory board from Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, Pharmamar, Novocure and MSD. Dr NS obtained commercial research grants from Eli Lilly, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, and Nippon Boehringer Ingelheim, and has received speaking honoraria from Eli Lilly, AstraZeneca, MSD Oncology, Chugai Pharmaceutical, Taiho Pharmaceutical, Pfizer Japan, Ono Pharmaceutical, Nippon Boehringer Ingelheim, and Bristol-Myers Squibb Japan. TH serves as an unpaid editorial board member of Translational Lung Cancer Research from Jan 2020 to Dec 2021. FC serves as an unpaid editorial board member of Translational Lung Cancer Research from Aug 2021 to Jul 2023. MF serves as an unpaid editorial board member of Translational Lung Cancer Research from

PY - 2021/9

Y1 - 2021/9

UR - http://www.scopus.com/inward/record.url?scp=85116377875&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85116377875&partnerID=8YFLogxK

U2 - 10.21037/tlcr-21-634

DO - 10.21037/tlcr-21-634

M3 - Article

AN - SCOPUS:85116377875

SN - 2218-6751

VL - 10

SP - 3713

EP - 3736

JO - Translational Lung Cancer Research

JF - Translational Lung Cancer Research

IS - 9

ER -

Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this